inclusion criteria: * sars-cov-2 infection documented by polymerase chain reaction (pcr) or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection * symptomatic covid-19 disease * duration of symptoms attributable to covid-19 ≤ 12 days * requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) * willingness to abstain from participation in other covid-19 treatment trials until after study day 7 * provision of informed consent by participant or legally authorized representative

inclusion criteria: * sars-cov-2 infection documented by polymerase chain reaction (pcr) or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection * symptomatic covid-19 disease * duration of symptoms attributable to covid-19 ≤ 12 days * requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) * willingness to abstain from participation in other covid-19 treatment trials until after study day 7 * provision of informed consent by participant or legally authorized representative

inclusion criteria: - sars-cov-2 infection documented by polymerase chain reaction (pcr) or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection - symptomatic covid-19 disease - duration of symptoms attributable to covid-19 ≤ 12 days - requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) - willingness to abstain from participation in other covid-19 treatment trials until after study day 7 - provision of informed consent by participant or legally authorized representative

inclusion criteria: - sars-cov-2 infection documented by polymerase chain reaction (pcr) or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection - symptomatic covid-19 disease - duration of symptoms attributable to covid-19 ≤ 12 days - requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) - willingness to abstain from participation in other covid-19 treatment trials until after study day 7 - provision of informed consent by participant or legally authorized representative

inclusion criteria: - sars-cov-2 infection documented by pcr or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection - symptomatic covid-19 disease - duration of symptoms attributable to covid-19 ≤ 12 days - requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) - willingness to abstain from participation in other covid-19 treatment trials until after study day 7 - provision of informed consent by participant or legally authorized representative

inclusion criteria: - sars-cov-2 infection documented by pcr or other nucleic acid test (nat) within 3 days prior to randomization or documented by nat more than 3 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection - symptomatic covid-19 disease - duration of symptoms attributable to covid-19 ≤ 12 days - requiring inpatient hospital medical care for clinical manifestations of covid-19 (admission for public health or quarantine only is not included) - willingness to abstain from participation in other covid-19 treatment trials until after study day 7 - provision of informed consent by participant or legally authorized representative